Frederick, Maryland, April 29, 2019: The University of Vermont Health Network Ventures and legal firm Wilson Sonsini Goodrich & Rosati recently invested in BioFactura’s $6M Series B Financing Round. “With the commitment from the UVM fund and WSGR, BioFactura is now securing value-added institutional investors who bring significant financial and business resources to bear as … Continue reading
Frederick, Maryland Jeffrey N. Hausfeld MD, MBA, Chairman and Chief Medical Officer, today announced that BioFactura will present at Biotech Showcase™ 2018, to be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square. Date: Wednesday, January 10, 2018 Time: 3:15 PM (PST) Room: Yosemite -B (Ballroom Level) Venue: … Continue reading
Annapolis, Maryland Today, Maryland Governor Larry Hogan signed into law a measure aimed at providing additional support to Maryland small biotechnology companies. Senate Bill 226 sponsored by Senator Roger Manno, and House Bill 373 sponsored by Delegate Darryl Barnes will support Maryland small and innovative biotech companies by amending the Biotechnology Investor Incentive Tax Credit … Continue reading
BioFactura, Inc. was granted patent rights by China’s State Intellectual Property Office (SIPO) protecting the core technologies of its proprietary StableFastTM Biomanufacturing Platform. SIPO allowed 17 claims broadly covering composition of matter and methods. StableFastTM is BioFactura’s proprietary NS0-based system to rapidly generate stable cell lines that have the potential to lower cost, produce follow-on … Continue reading
BioFactura, Inc., an emerging Maryland biopharmaceutical research and manufacturing company, announced today entry into a non-exclusive license agreement with Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, relating to one of the biosimilar product candidates that Momenta is developing. As part of this non-exclusive license agreement, … Continue reading
BioFactura announced today the closing of a $1.8M Series A round of financing. Healthy investor interest drove significant oversubscription of the original $1.5M target. The funds will be used to advance a portfolio of generic biologics, known as biosimilars, to the advanced preclinical stages. Chief Executive Officer and President, Darryl Sampey founded BioFactura in 2004 as … Continue reading
BioFactura proudly announces the appointment of Dr. Jeffrey Hausfeld as the newly elected Chairman of the Board and Chief Medical Officer. Dr. Hausfeld, a graduate from Yale University School of Medicine, practiced Otolaryngology and Facial Plastic Surgery in the Washington DC area for more than 23 years until he ventured into the business side of … Continue reading